Department of Defense PTSD Adaptive Platform Trial Intervention A - Fluoxetine
Study Details
Study Description
Brief Summary
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention A - Fluoxetine will assess the safety and efficacy of fluoxetine in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
The general structure of this Adaptive Platform Trial (APT) consists of a 30-day Screening Period, a 12-week Platform Treatment Period, and a 4-week Safety Follow-up. The S-21-02 Platform Trial will evaluate the safety and efficacy of multiple investigational products for the treatment of PTSD (see NCT05422612 for Master Protocol information). Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control subjects, where all interventions may be compared to a common control (placebo). This record only includes information relevant to the fluoxetine cohort.
Once a participant meets all eligibility criteria for the Master Protocol, eligibility for each currently enrolling intervention cohort is assessed. Eligible participants will be randomized with equal probability into a cohort. Participants randomized to the fluoxetine cohort are then randomly assigned to receive either fluoxetine or placebo in a ratio defined by the number of cohorts for which they are eligible, for the duration of the 12-week treatment period (Viele et al 2023).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Intervention A: Fluoxetine HCl
|
Drug: Intervention A Fluoxetine HCl
Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
|
Placebo Comparator: Intervention A Placebo
|
Drug: Intervention A Placebo
A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
|
Outcome Measures
Primary Outcome Measures
- Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/ET Visit). [12 Weeks]
A change in PTSD symptom severity from baseline as measured by CAPS-5-R Past Month. The range of the scale is 0-200. The higher the score at baseline, the worse the PTSD severity. The larger the decrease in score from baseline, the better the outcome.
- Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline. [12 Weeks]
The C-SSRS is an assessment of suicidal ideation and behavior in clinical and research settings. The C-SSRS consists of 16 questions that ask about suicidal ideation and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). This 5-item subscale ranges from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent).
Secondary Outcome Measures
- Frequency of treatment-emergent adverse events (TEAEs). [12 Weeks]
The TEAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA.
- Severity of treatment-emergent adverse events (TEAEs). [12 Weeks]
The TEAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA.
- Frequency of serious adverse events (SAEs). [12 Weeks]
The SAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA.
- Severity of serious adverse events (SAEs). [12 Weeks]
The SAEs recorded during the study will be summarized by system organ class, preferred term, and treatment group. Adverse events and medical history will be coded using the most current version of MedDRA.
- Relative change from Baseline to Week 12 in CAPS-5-R, Past Month total score. [12 Weeks]
A relative change in PTSD symptom severity from baseline as measured by CAPS-5-R Past Month. The range of the scale is 0-200. The higher the score at baseline, the worse the PTSD severity. The larger the decrease in score from baseline, the better the outcome.
- Number of participants with a Response Rate ≥30% [12 Weeks]
≥30% reduction from Baseline to 12 Weeks in CAPS-5-R, Past Month total score.
- Number of participants with a Response Rate ≥50% [12 Weeks]
≥50% reduction from Baseline to 12 Weeks in CAPS-5-R, Past Month total score.
- Number of participants Achieving Remission [12 Weeks]
Achieving remission: defined as CAPS-5-R, Past Month total score <18.
Eligibility Criteria
Criteria
Inclusion Criteria:
No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT05422612).
Exclusion Criteria:
The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT04297683).
- Recent history of treatment for PTSD with fluoxetine at doses of 20 mg daily, for at least 8 weeks. A remote history of treatment with fluoxetine for non-PTSD symptoms will be discussed on a case-by-case basis with the CRO Medical Monitor.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- U.S. Army Medical Research and Development Command
- PPD
- Berry Consultants
- Idorsia Pharmaceuticals Ltd.
- Cambridge Cognition Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- S-21-02 (Fluoxetine)